Jan 12 (Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.



Latest News

USA Today: Kang finishes strong to win LPGA Shanghai by 2 strokes

USA Today: Kang finishes strong to win LPGA Shanghai by 2 strokes

Daily Mail: Today show weather presenter Natalia Cooper recalls meeting her hubby Carl Fox at a pub in Perth

Daily Mail: Merrick demands better from VAR officials

Daily Mail: Hawks overcome Cairns NBL hoodoo

Daily Mail: Officials play 'war games' on how they might call and run a second referendum on Brexit

FOX: Trump rallies in Clinton-won districts ahead of midterms

Daily Mail: US Mega Millions jackpot hits 1.6bn dollars

Daily Mail: Pregnant Meghan takes break from Australia royal tour

Daily Mail: Agatha Christie's taste for poison was inspired by her experiences as a wartime nurse

Daily Mail: King Henry VIII was a 'vulnerable, insecure and loyal' king, says expert

Reuters: China says must balance stable growth and risk prevention

Haaretz: A timeline of Saudi Arabia's shifting narratives on Jamal Khashoggi's death

NewYorkTimes: ‘The Miseducation of Lauryn Hill’ Kids, 20 Years Later

Daily Mail: Bank of England remains under fire over `staggeringly´...

Daily Mail: Next Bank of England chief does not need to be a woman,...

Daily Mail: Man slashed on the face, back, shoulders and arms by friend armed with a box cutter in Potts Point

Daily Mail: Kang finishes strong to win LPGA Shanghai by 2 strokes

Reuters: Iran's Rouhani appoints new economy minister in reshuffle

Jpost: Russia: U.S. withdrawal from nuclear treaty is a dangerous step

FOX: VIDEO: Police officers help free deer caught in fence

BBC: Scotland's papers: Plans for first film studio

ABC: 5 major issues dominating the midterm elections: ANALYSIS